Investigating how to improve regulatory T cell development from stem cells for autoimmune diseases
Dynamic FOXP3 Expression in the Development of Regulatory T cells from Induced Pluripotent Stem Cells
This study is working on new treatments for autoimmune diseases by finding better ways to create special immune cells called regulatory T cells from stem cells, which could help people with these conditions feel better.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11054847 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies for autoimmune diseases by enhancing the production of regulatory T cells (Tregs) from induced pluripotent stem cells (iPSCs). The team will explore how to stabilize the expression of the FOXP3 gene, which is crucial for Treg function, using innovative techniques like artificial thymic organoids and CRISPR/Cas9 technology. By comparing these lab-generated Tregs with naturally occurring ones, the researchers aim to create a more effective cellular therapy for patients suffering from autoimmune conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune diseases who may benefit from advanced cellular therapies.
Not a fit: Patients with non-autoimmune conditions or those who do not respond to cellular therapies may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for autoimmune diseases, potentially reducing disability and improving quality of life for millions of patients.
How similar studies have performed: Previous research has shown promise in using stem cells for Treg development, indicating a potential for success in this novel approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Yiu, Gloria — University of California Los Angeles
- Study coordinator: Yiu, Gloria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.